Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Eyerising RS-200-2A, Airdoc Sky-n1201.
- Who it may be relevant to
- Registry conditions: Myopia. Basic parameters: 18 years — 35 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study on the Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies for Adult Myopia Treatment
Overview
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light
Detailed description
The experiment will be divided into two phases. In the first phase, the subjects will be randomly grouped using laser equipment and LED equipment, and each group will be exposed to the red light twice a day for one month. The second stage involves self-comparison of the laser equipment, with the usage frequencies being once a day and three times a day.
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light in different devices and frequencies, as well as its impact on the axial length, spherical equivalent refraction and choroidal thickness of myopia progression.
Interventions
- Device Eyerising RS-200-2A
Eyerising RS-200-2A,1 time,2 times, 3 times a day - Device Airdoc Sky-n1201
Eyerising RS-200-2A,2 times a day
Primary outcome measures
- Axial length [Time frame: From enrollment to the end of treatment up to 7 months]
Secondary outcome measures (2)
- Spherical equivalent [Time frame: From enrollment to the end of treatment up to 7 months]
- Choroidal thickness [Time frame: From enrollment to the end of treatment up to 7 months]
Eligibility criteria
Inclusion criteria
- 18-35 years old, gender not limited; Obtained informed consent.
Exclusion criteria
- Obvious strabismus and amblyopia
- With congenital eye disease, such as congenital cataract, congenital retinal disease
- Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
- Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
- Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
- Bnormal intraocular pressure and clinical significance (IOP <10 mmHg or IOP>21mmHg or binocular IOP difference ≥5mmHg)
- Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
- Optic nerve damage or congenital optic nerve dysfunction
- Can not be regularly checked
- The adjustment range is less than 8D or obvious near difficulties
- Other reasons researchers think it is not suitable for inclusion in researchers
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Tianjin Medical University Eye Hospital — Tianjin
Identifiers
NCT: NCT07186088 · 2025YK-54